Testing a new drug combo for HER2-positive advanced breast cancer
Part of Cancer, Skin clinical trials.
This trial tests two study drugs, HLX22 and HLX87, together for people with HER2-positive breast cancer that has spread or come back. It may be an option if you haven't yet had chemotherapy or HER2-targeted therapy for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your breast cancer must be HER2-positive (a specific protein found on the cancer cells).
- You cannot have had chemotherapy or cancer-targeting therapy for advanced or metastatic breast cancer before (but you can have had hormone therapy).
- You must have at least one tumor that can be measured on a scan.
- You should be generally active and able to take care of yourself (ECOG score 0 or 1).
- You must not have had certain previous treatments, like high-dose doxorubicin or certain antibody-drug conjugates.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HLX22 combined with standard treatments (trastuzumab and chemotherapy) for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. The goal is to see if this combination helps shrink tumors or slow the cancer's growth.
This study tests a new combination of targeted drugs (HLX87 with HLX22 or pertuzumab) given before breast cancer surgery. The goal is to shrink the tumor and improve treatment outcomes for people with HER2-positive breast cancer.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests a new drug, HLX22, combined with Enhertu (trastuzumab deruxtecan) for people with advanced breast cancer that is hormone receptor positive and HER2-low. The goal is to see if the combination works better than Enhertu alone.
This trial tests a new drug (HLX43) for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests adding a new drug, HLX22, to the standard combination of trastuzumab and chemotherapy for people with HER2-positive stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if this three-drug mix works better than the usual two-drug approach.
Hear when a new HER2 + Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.